{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:02:01Z","timestamp":1774677721782,"version":"3.50.1"},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12185-025-03960-y","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T18:39:28Z","timestamp":1742841568000},"page":"746-755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma 4. Mantle cell lymphoma (MCL)"],"prefix":"10.1007","volume":"121","author":[{"given":"Kenichi","family":"Ishizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03960-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03960-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03960-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:32:27Z","timestamp":1748259147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03960-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3960"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03960-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KI has received per diem, including speaking fees, from Takeda Pharmaceuticals, Novartis Pharma, Janssen Pharmaceutical, Ono Pharmaceutical, Chugai Pharmaceutical, Sanofi, Bristol Myers Squibb, MSD, Eisai, Otsuka Pharmaceutical, Kyowa Kirin, IQVIA Services Japan, Micron, and Sawai Pharmaceutical; and has received research funding from Otsuka Pharmaceutical, Pfizer, SymBio Pharmaceuticals, AbbVie, Sanofi, Novartis Pharma, Chugai Pharmaceutical, IQVIA Services Japan, and Zenyaku Kogyo. KY has received per diem, including speaking fees, from AbbVie, IQVIA Services Japan\/HUYA Bioscience International, Eisai, Chugai Pharmaceutical, Meiji Seika Pharma, Micron\/Daiichi Sankyo, and Janssen Pharmaceutical; and has received research funding from IQVIA Services Japan\/Genmab, IQVIA Services Japan\/Incyte Biosciences Japan, and Yakult Honsha.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}